You are here: Industry Insights > Innate Pharma

News List

T-cell lymphomas treatment trial update announced by Innate Pharma europeanpharmaceuticalreview
January 13, 2020
Enrolment of new patients in the TELLOMAK trial, which has been evaluating the efficacy and safety of lacutamab in patients with advanced T-cell lymphomas, has been suspended.
Innate Pharma gains rights to AZ’s recently approved leukaemia drug pharmaphorum
December 21, 2018
France’s Innate Pharma has gained rights to AstraZeneca’s recently approved leukaemia drug Lumoxiti, in a deal that expands a collaboration that began more than three years ago.
AstraZeneca to buy 9.8% stake in France’s Innate Pharma expressbpd
October 24, 2018
AstraZeneca will buy the stake via around 6.26 million new shares
Innate Pharma acquires anti-C5aR antibody from Novo Nordisk pharmaceutical-technology
June 06, 2017
French biotechnology company Innate Pharma has signed an agreement to acquire a clinical-stage anti-C5a receptor (C5aR) antibody (IPH5401) from Danish pharmaceutical firm Novo Nordisk for €40m.